A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

Study type: Clinical Trials Posting date: 04/16/2025 Last updated: 04/16/2025 Status: Recruiting Phase: 1B/2A Country: USA and Canada Eligibility:

Between ages 18 – 55; diagnosis of alopecia areata; alopecia areata lesions (patches) that can accommodate treatment or placebo injections
Drug: ALD-102 Solution/placebo Administration: Intralesional injections Sponsor: Alys Pharmaceuticals ClinicalTrials.gov link: Click here Location: Multiple locations


 Description:

This first-in-human clinical trial aims to learn if ALD-102 Solution is safe and well tolerated following injections in the scalp in subjects with alopecia areata. The study will also learn about the effect of ALD-102 on hair regrowth in treatment areas. The researchers will compare the effects of ALD-102 Solution (drug) to placebo (saline solution that contains no drug). Study participants will have two treatment areas selected on the scalp and will randomly receive ALD-102 Solution (drug) at one area and/or placebo (saline solution) at the other area once every 4 weeks for a treatment period of 8 weeks.

You may qualify to participate in this study if you:

  • Are between the ages 18 – 55
  • Have a clinically confirmed diagnosis of AA at screening visit, based on the investigator’s judgement.
  • Have AA lesion(s) (patches) that can accommodate for two separate treatment areas large enough to receive 20 injections each or to receive 40 injections each.

There are additional requirements as determined by a screening process.

For more information, visit this ClinicalTrials.Gov page or contact a study site location.

 

Indiana
West Lafayette, Indiana, United States, 47906
Options Research Group

Washington
Spokane, Washington, United States, 99202
Dermatology Specialists of Spokane

Canada
Quebec, Canada, QC G1W 4R4
Centre de Recherche Saint-Louis

Oakville, Ontario, Canada, L6J 7W5
The Centre for Clinical Trials

Montreal, Quebec, Canada, H2X 2V1
Innovaderm